



US008211447B2

(12) **United States Patent**  
**Angov et al.**

(10) **Patent No.:** **US 8,211,447 B2**  
(45) **Date of Patent:** **Jul. 3, 2012**

(54) **RECOMBINANT *P. FALCIPARUM* MEROZOITE PROTEIN-1<sub>42</sub> VACCINE**

(75) Inventors: **Evelina Angov**, Bethesda, MD (US);  
**Jeffrey A. Lyon**, Silver Spring, MD (US);  
**Christian Asare Darko**, Silver Spring, MD (US);  
**Joe D. Cohen**, Brussels (BE)

(73) Assignee: **The United States of America as represented by the Secretary of the Army**, Washington, DC (US)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **12/507,004**

(22) Filed: **Jul. 21, 2009**

(65) **Prior Publication Data**

US 2010/0028386 A1 Feb. 4, 2010

**Related U.S. Application Data**

(60) Continuation of application No. 11/889,578, filed on Aug. 14, 2007, now Pat. No. 7,563,883, which is a division of application No. 10/404,667, filed on Apr. 1, 2003, now Pat. No. 7,256,281.

(60) Provisional application No. 60/379,688, filed on May 9, 2002.

(51) **Int. Cl.**

**A61K 39/015** (2006.01)  
**A61K 38/00** (2006.01)

(52) **U.S. Cl.** ..... **424/268.1; 424/184.1**

(58) **Field of Classification Search** ..... None  
See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

4,978,621 A 12/1990 Ardeshir et al.  
5,082,767 A 1/1992 Hatfield et al.  
6,551,586 B1 4/2003 Davidson et al.  
7,501,553 B2 3/2009 Chen et al.

**FOREIGN PATENT DOCUMENTS**

CA 2245727 8/1997  
WO WO-9730159 A2 8/1997  
WO WO-0063245 A2 10/2000  
WO WO-01/34188 A1 5/2001  
WO WO-0168835 A2 9/2001

**OTHER PUBLICATIONS**

Angov et al., "Process Development for Clinical Grade *Plasmodium falciparum* MSP1/42 (3D7) Expressed in *E. coli*", American Journal of Tropical Medicine & Hygiene, Lawrence, Nov. 28, 1999, p. 207, vol. 61, No. 3.

Angov, E. et al. 2003. Development and Pre-Clinical Analysis of a *Plasmodium falciparum* Merozoite Surface Protein-1 42 Malaria Vaccine. Molecular & Biochemical Parasitology 128, 195-204.

Chang, S.P. et al. 1996. A Recombinant Baculovirus 42-Kilodalton C-Terminal Fragment of *Plasmodium falciparum* Merozoite Surface Protein 1 Protects Aotus Monkeys Against Malaria. infection and immunity 64, 253-261.

Dutta et al., Purification, Characterization, and Immunogenicity of a Disulfide Cross-Linked *Plasmodium vivax* Vaccine Candidate Antigen Merozoite Surface Protein 1 Expressed in *Escherichia coli*, Infection and Immunity, American Society for Microbiology, Sep. 2001, pp. 5464-5470, vol. 69, No. 9.

Genton, B. et al., 200. Safety and Immunogenicity of a Three-Component Blood-Stage Malaria Vaccine in Adults Living in an Endemic Area of Papua New Guinea. Vaccine 18, 2504-2511.

Gento, B. et al. 2002. A Recombinant Blood-Stage Malaria Vaccine Reduces *Plasmodium falciparum* Density and Exerts Selective Pressure on Parasite Population in a Phase 1-2B Trial in Papua New Guinea. J. of Infectious Disease 185, 820-827.

Kumar, S. et al., 1995. Immunogenicity and In Vivo Efficacy of Recombinant *Plasmodium falciparum* Merozoite Surface Protein-1 in Aotus Monkeys. Molecular Medicine 1, 325-332.

Kumar, S. et al., 2002. A DNA Vaccine Encoding the 42KDA C-Terminus of Merozoite Surface Protein 1 of *Plasmodium falciparum* Induces Antibody, Interferon-γ and Cytotoxic T Cell Responses in Rhesus Monkey: Immuno-Stimulatory Effects of Granulocyte Macrophage-Colony Stimulating Factor. Immunology Letter 81, 13-24.

Longarce, S., et al., Mol. Biochem. Parasitol.

Pang et al., "In Vivo Expression and Immunological Studies of the 42-Kilodalton Carboxyl-Terminal Processing Fragment of *Plasmodium falciparum* Merozoite Surface Protein 1 in the Baculovirus-Silkworm System," Infection and Immunity, Jun. 2002, pp. 2772-2779, vol. 70, No. 6.

Qian et al., "Inducible Expression of MSP1 Gene of *Plasmodium falciparum* by a Tetracycline-Controlled Promoter", Chinese Journal of Parasitology & Parasitic Diseases, 2000, pp. 193-196, vol. 18, No. 4. (with English Abstract).

Weiqing et al., "Vaccine Candidate MSP-1 From *Plasmodium falciparum*: A Redesigned 4917 BP Polynucleotide Enables Synthesis and Isolation of Full-Length Protein From *Escherichia coli* and Mammalian Cells", Nucleic Acids Research, 199, pp. 1094-1103, vol. 27, No. 4.

Thanaraj, T.A. et al., 1996. Ribosome-mediated translational pause and protein domain organization. Protein Science 5, p. 1594-1612.

Komar A.A. et al., 1999. Synonymous codon substitutions affect ribosome traffic and protein folding during in vitro translation. FEBS Letters, 462, p. 387-391.

Martin, S.L. et al., 1995. Total synthesis and expression in *Escherichia coli* of a gene encoding human tropoelastin. Gene 154, p. 159-166.

Purvis, I.J. et al., 1987. The efficiency of folding of some proteins is increased by controlled rates of translation in-vivo a hypothesis. J. of Molecular Biology 193, p. 413-418.

Nakamura, Y. et al., 2000. Codon usage tabulated from international DNA sequence databases; status for the year 2000. Nucleic Acids Research 28, p. 292.

McGarvey, M.J. et al., "Identification and expression in *Escherichia coli* of merozoite stage-specific genes of the human malarial parasite *Plasmodium falciparum*," Proc. Natl. Acad. Sci. USA, vol. 81, pp. 3690-3694, Jun. 1984.

EP Application No. 03 726 192.2, Issued Office Action Oct. 12, 2009.

*Primary Examiner* — Padma Baskar

(74) *Attorney, Agent, or Firm* — Elizabeth Arwine

(57) **ABSTRACT**

In this application is described the expression and purification of a recombinant *Plasmodium falciparum* (FVO) MSP-1<sub>42</sub>. The method of the present invention produces a highly purified protein that retains folding and disulfide bridging of the native molecule. The recombinant MSP-1<sub>42</sub> is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.